EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study

Borje Darpo, Kalvin Connor, Christopher H Cabell, John S Grundy

Clinical Pharmacology in Drug Development · 2024-04 · 13 (4) · 326-340

DOI: 10.1002/cpdd.1388 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 05.03.2024. Verfasst von Borje Darpo und 3 weiteren Autor:innen. Beteiligte Einrichtung: ERT, Rochester, NY, USA. Hauptthemen laut MEDLINE: Fluoroquinolones, Electrocardiography, Acetates, Indoles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Etrasimod is an investigational, once‐daily, oral, selective sphingosine 1‐phosphate receptor 1,4,5 modulator used as an oral treatment option for immune‐mediated inflammatory disorders. This randomized, double‐blind, placebo‐ and positive‐controlled, parallel‐group, healthy adult study investigated etrasimod's effect on the QT interval and other electrocardiogram parameters. All participants received etrasimod‐matched placebo on day 1. Group A received once‐daily, multiple ascending doses of etrasimod (2‐4 mg) on days 1‐14 and moxifloxacin‐matched placebo on days 1 and 15. Group B received etrasimod‐matched placebo on days 1‐14 and either moxifloxacin 400 mg or moxifloxacin‐matched placebo on days 1 and 15. The primary analysis was a concentration‐QTc analysis using a corrected QT interval by Fridericia (QTcF). The etrasimod concentration‐QTc analysis predicted placebo‐corrected change from baseline QTcF (ΔΔQTcF) values and associated 90% confidence intervals remained

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesElectrocardiographyAcetatesIndolesAdultHumansMoxifloxacinSphingosine-1-Phosphate Receptors

Stichwörter der Autor:innen

QT correction (QTc)etrasimodheart ratepharmacokinetics

Substanzen

MoxifloxacinFluoroquinolonesetrasimodSphingosine-1-Phosphate ReceptorsAcetatesIndoles

Autor:innen und Institutionen

  • ERT, Rochester, NY, USA.
  • Arena Pharmaceuticals, San Diego, CA, USA, a wholly-owned subsidiary of Pfizer Inc, New York, NY, USA.

Zitieren

APA

Darpo, B., Connor, K., Cabell, C. H., & Grundy, J. S. (2024). Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study. Clinical Pharmacology in Drug Development, 13(4), 326-340. https://doi.org/10.1002/cpdd.1388

Vancouver

Darpo B, Connor K, Cabell CH, Grundy JS. Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study. Clinical Pharmacology in Drug Development. 2024;13(4):326-340. doi:10.1002/cpdd.1388

BibTeX
@article{Darpo2024,
  author = {Darpo, Borje and Connor, Kalvin and Cabell, Christopher H and Grundy, John S},
  title = {Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {326--340},
  doi = {10.1002/cpdd.1388}
}
Kostenlos starten →